Literature DB >> 6505043

Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers.

H J Weinmann, M Laniado, W Mützel.   

Abstract

Pharmacokinetic studies of GdDTPA/dimeglumine in man show a rapid renal clearance and no evidence for dissociation or retention of the complex in the body. These features, in conjunction with its strong proton relaxation enhancement and its low toxicity suggest that this complex may be an excellent contrast medium for magnetic resonance imaging.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6505043

Source DB:  PubMed          Journal:  Physiol Chem Phys Med NMR        ISSN： 0748-6642


  106 in total

Review 1.  The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists.

Authors:  Mariane Le Fur; Peter Caravan
Journal:  Metallomics       Date:  2019-02-20       Impact factor: 4.526

Review 2.  CMR for characterization of the myocardium in acute coronary syndromes.

Authors:  Erica Dall'Armellina; Theodoros D Karamitsos; Stefan Neubauer; Robin P Choudhury
Journal:  Nat Rev Cardiol       Date:  2010-09-21       Impact factor: 32.419

Review 3.  Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy.

Authors:  Anwar R Padhani; Aftab Alam Khan
Journal:  Target Oncol       Date:  2010-04-11       Impact factor: 4.493

4.  Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.

Authors:  Stylianos Drisis; Thierry Metens; Michael Ignatiadis; Konstantinos Stathopoulos; Shih-Li Chao; Marc Lemort
Journal:  Eur Radiol       Date:  2015-08-27       Impact factor: 5.315

Review 5.  Contrast medium administration and image acquisition parameters in renal CT angiography: what radiologists need to know.

Authors:  Charbel Saade; Ibrahim Alsheikh Deeb; Maha Mohamad; Hussain Al-Mohiy; Fadi El-Merhi
Journal:  Diagn Interv Radiol       Date:  2016 Mar-Apr       Impact factor: 2.630

Review 6.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

7.  Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.

Authors:  Adam C Yopp; Lawrence H Schwartz; Nancy Kemeny; David H Gultekin; Mithat Gönen; Zubin Bamboat; Jinru Shia; Dana Haviland; Michael I D'Angelica; Yuman Fong; Ronald P DeMatteo; Peter J Allen; William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2011-02-01       Impact factor: 5.344

8.  Sensitivity analysis of an image-based solid tumor computational model with heterogeneous vasculature and porosity.

Authors:  Gregory L Pishko; Garrett W Astary; Thomas H Mareci; Malisa Sarntinoranont
Journal:  Ann Biomed Eng       Date:  2011-07-13       Impact factor: 3.934

Review 9.  Breast cancer imaging: a perspective for the next decade.

Authors:  Andrew Karellas; Srinivasan Vedantham
Journal:  Med Phys       Date:  2008-11       Impact factor: 4.071

Review 10.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.